indication

Chronic Schizophrenia

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
3
2 approved · 1 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
30 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 31 trial
OwnerSumitomo Pharmaceuticals America
Protection2031
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 31 trial
OwnerAstraZeneca
Protection—
drugCompleted
Evenamide
Pipeline · Phase 2
Phase 21 trial
OwnerNewron Pharmaceuticals SPA
Protection—

Market size

prevalence as a range, not a number